• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sleep Disorders - Pipeline Review, Q3 2011 - Product Image

Sleep Disorders - Pipeline Review, Q3 2011

  • Published: July 2011
  • 136 pages
  • Global Markets Direct

Sleep Disorders - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Sleep Disorders - Pipeline Review, Q3 2011', provides an overview of the Sleep Disorders therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sleep Disorders. 'Sleep Disorders - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sleep Disorders.
- A review of the Sleep Disorders products under development by companies and universities/research institutes based on information READ MORE >



List of Tables
List of Figures
Introduction
Sleep Disorders Overview
Therapeutics Development
Sleep Disorders Therapeutics under Development by Companies
Sleep Disorders Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Sleep Disorders Therapeutics - Products under Development by Companies
Sleep Disorders Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Sleep Disorders Therapeutics Development
Sleep Disorders - Therapeutics Assessment
Late Stage Drug Profiles
Sleep Disorders Therapeutics – Drug Profile Updates
Sleep Disorders Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Sleep Disorders, Q3 2011
Products under Development for Sleep Disorders – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Johnson & Johnson, 2011
Abbott Laboratories, 2011
Sanofi-Aventis, 2011
Eli Lilly and Company, 2011
Athersys, Inc., 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
Dainippon Sumitomo Pharma Co., Ltd., 2011
Takeda Pharmaceutical Company Limited, 2011
Alexza Pharmaceuticals, Inc., 2011
Neurocrine Biosciences, Inc., 2011
Eisai Co., Ltd., 2011
Pfizer Inc., 2011
Bayer AG, 2011
Addex Pharmaceuticals, 2011
Evotec Aktiengesellschaft, 2011
IntelGenx Technologies Corp., 2011
Ligand Pharmaceuticals Incorporated, 2011
NovaDel Pharma, Inc., 2011
ACADIA Pharmaceuticals Inc., 2011
Arena Pharmaceuticals, Inc., 2011
Jazz Pharmaceuticals, Inc., 2011
Transcept Pharmaceuticals, Inc., 2011
Neurim Pharmaceuticals (1991) Ltd., 2011
Abeille Pharmaceuticals, Inc., 2011
Intec Pharma ltd., 2011
CoLucid Pharmaceuticals, Inc., 2011
Fabre-Kramer Pharmaceuticals, Inc., 2011
Ferrer Internacional S.A., 2011
Rottapharm SpA, 2011
Somnus Therapeutics, Inc., 2011
Intra-Cellular Therapies, Inc., 2011
Vanda Pharmaceuticals Inc., 2011
Heptares Therapeutics Ltd., 2011
Eurofarma, 2011
BIOPROJET SCR, 2011
Mayne Pharma Limited, 2011
Phase 2 Discovery, Inc., 2011
SK Bio-Pharmaceuticals, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Sleep Disorders Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Sleep Disorders, Q3 2011
Products under Development for Sleep Disorders – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos